POM121 overexpression is related to a poor prognosis in colorectal cancer

References

• Bundgaard-Nielsen C, Baandrup UT, Nielsen LP, et al. The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue. BMC Cancer. 2019;19:399.
   PubMed Web of Science ®Google Scholar
• Coppede F, Lopomo A, Spisni R, et al. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 2014;20:943–956.
   PubMed Web of Science ®Google Scholar
• Geng F, Wang Z, Yin H, et al. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives. Cancer Biother Radiopharm. 2017;32:149–160.
   PubMed Web of Science ®Google Scholar
• Oconnell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. J Natl Cancer Inst. 2005;96:1420–1425.
   Google Scholar
• Jin J. Screening for colorectal cancer. JAMA. 2016;315:2635.
   PubMedGoogle Scholar
• Burch J, Soaresweiser K, John DJBS, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14:132–137.
   PubMed Web of Science ®Google Scholar
• Shaulov L, Gruber R, Cohen I, et al. A dominant-negative form of POM121 binds chromatin and disrupts the two separate modes of nuclear pore assembly. J Cell Sci. 2011;124:3822–3834.
   PubMed Web of Science ®Google Scholar
• Antonin W, Franz C, Haselmann U, et al. The integral membrane nucleoporin pom121 functionally links nuclear pore complex assembly and nuclear envelope formation. Mol Cell. 2005;17:83–92.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Mansfeld J, Capitanio J, et al. Pom121 links two essential subcomplexes of the nuclear pore complex core to the membrane. J Cell Biol. 2010;191:505–521.
   PubMed Web of Science ®Google Scholar
• Sevil Y, Rachel SM, Birgit K, et al. NLS-mediated NPC functions of the nucleoporin Pom121. FEBS Lett. 2010;584:3292–3298.
   PubMed Web of Science ®Google Scholar
• Saito H, Takeuchi H, Masuda T, et al. N-terminally truncated POM121C inhibits HIV-1 replication. PLoS One. 2017;12:e0182434.
   PubMed Web of Science ®Google Scholar
• Guo J, Liu X, Wu C, et al. The transmembrane nucleoporin Pom121 ensures efficient HIV-1 pre-integration complex nuclear import. Virology. 2018;521:169–174.
   PubMed Web of Science ®Google Scholar
• Ge W, Yue Y, Xiong S. POM121 inhibits the macrophage inflammatory response by impacting NF-kappaB P65 nuclear accumulation. Exp Cell Res. 2019;377:17–23.
   PubMed Web of Science ®Google Scholar
• Fortschegger K, Anderl S, Denk D, et al. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development. Mol Cancer Res. 2014;12:595–606.
   PubMed Web of Science ®Google Scholar
• Denk D, Bradtke J, Konig M, et al. PAX5 fusion genes in t(7;9)(q11.2;p13) leukemia: a case report and review of the literature. Mol Cytogenet. 2014;7:13.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bravo V, Pippa R, Song WM, et al. Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import. Cell. 2018;174:1200–1215 e1220.
   PubMed Web of Science ®Google Scholar
• Ning QY, Wu JZ, Zang N, et al. Key pathways involved in prostate cancer based on gene set enrichment analysis and meta analysis. Genet Mol Res. 2011;10:3856–3887.
   PubMed Web of Science ®Google Scholar
• Raices M, D’Angelo MA. Nuclear pore complexes and regulation of gene expression. Curr Opin Cell Biol. 2017;46:26–32.
   PubMed Web of Science ®Google Scholar
• Alfonso P, Canamero M, Fernandezcarbonie F, et al. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res. 2008;7:4247–4255.
   PubMed Web of Science ®Google Scholar
• Singer S, Zhao R, Barsotti A, et al. Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell. 2012;48:799–810.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhao Z, Jiang L, et al. Nup88 expression in normal mucosa, adenoma, primary adenocarcinoma and lymph node metastasis in the colorectum. Tumor Biol. 2007;28:93–99.
   PubMedGoogle Scholar
• Li Y, Zhang X, Ge J, et al. Can Nup88 expression be associated with atypical endometrial hyperplasia and endometrial cancer? A preliminary study. Pathol Res Pract. 2016;212:274–278.
   PubMed Web of Science ®Google Scholar
• Agudo D, Gomezesquer F, Martinezarribas F, et al. Nup88 mRNA overexpression is associated with high aggressiveness of breast cancer. Int J Cancer. 2004;109:717–720.
   PubMed Web of Science ®Google Scholar
• Hazawa M, Lin D, Kobayashi A, et al. ROCK‐dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation. EMBO Rep. 2018;19:73–88.
   PubMed Web of Science ®Google Scholar
• Labade AS, Karmodiya K, Sengupta K. HOXA repression is mediated by nucleoporin Nup93 assisted by its interactors Nup188 and Nup205. Epigenetics Chromatin. 2016;9:54.
   PubMed Web of Science ®Google Scholar
• Vecchione L, Gambino V, Raaijmakers JA, et al. A vulnerability of a subset of colon cancers with potential clinical utility. Cell. 2016;165:317–330.
   PubMed Web of Science ®Google Scholar
• Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226:352–364.
   PubMed Web of Science ®Google Scholar
• Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene. 2015;34:1–14.
   PubMed Web of Science ®Google Scholar
• Li Y, Guo H, Jin C, et al. Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer. Exp Cell Res. 2017;357:124–134.
   PubMed Web of Science ®Google Scholar
• Lim KS, Wong RW. Targeting Nucleoporin POM121-Importin β Axis in Prostate Cancer. Cell Chem Biol. 2018;25:1056–1058.
   PubMed Web of Science ®Google Scholar
• Maiuri AR, Peng M, Sriramkumar S, et al. Mismatch repair proteins initiate epigenetic alterations during inflammation-driven tumorigenesis. Cancer Res. 2017;77:3467–3478.
   PubMed Web of Science ®Google Scholar
• Marsden CG, Dragon J, Wallace SS, et al. Base excision repair variants in cancer. Methods Enzymol. 2017;591:119–157.
   PubMed Web of Science ®Google Scholar
• Bretones G, Delgado MD, Leon J. Myc and cell cycle control. Biochim Biophys Acta. 2015;1849:506–516.
   PubMed Web of Science ®Google Scholar
• Anczukow O, Krainer AR. The spliceosome, a potential Achilles heel of MYC-driven tumors. Genome Med. 2015;7:107.
   PubMed Web of Science ®Google Scholar
• Alidousty C, Baar T, Martelotto LG, et al. Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations. J Pathol. 2018;246:67–76.
   PubMed Web of Science ®Google Scholar
• Sur S, Nakanishi H, Steele R, et al. Depletion of PCAT-1 in head and neck cancer cells inhibits tumor growth and induces apoptosis by modulating c-Myc-AKT1-p38 MAPK signalling pathways. BMC Cancer. 2019;19:354.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Mottok A, Benneriah S, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact. Blood. 2017;129:2760–2770.
   PubMed Web of Science ®Google Scholar
• Woo SH, Seo S, An S, et al. Implications of caspase-dependent proteolytic cleavage of cyclin A1 in DNA damage-induced cell death. Biochem Biophys Res Commun. 2014;453:438–442.
   PubMed Web of Science ®Google Scholar
• Pozo PN, Matson JP, Cole Y, et al. Cdt1 variants reveal unanticipated aspects of interactions with cyclin/CDK and MCM important for normal genome replication. Mol Biol Cell. 2018;29:2989–3002.
   Web of Science ®Google Scholar